BUSINESS

Hokuriku Downpours Cripple Some Drug Deliveries; Wholesalers Report No Damage

By Tatsuya Otsuka August 28, 2026

Record-breaking rainfall hit Ishikawa and Toyama prefectures on August 27, prompting the highest-level emergency alert, with some drug deliveries suspended due to poor road conditions even as wholesalers reported no injuries or damage to their facilities.

Jiho contacted five wholesalers operating in the Hokuriku central Japan region, where the prefectures are located, on the same day. Medipal Holdings, Suzuken, Toho Holdings, Alfresa Holdings, which operates in Hokuriku through its Kanazawa-based subsidiary Meisho, and local wholesaler Fines all confirmed no injuries to employees or damage to their business sites.

While most reported no major impact on drug deliveries, Fines had to cancel some of its twice-daily deliveries in the Himi area of Toyama, one of the hardest-hit locations. Some deliveries also could not be made in parts of the Hakui area in Ishikawa.

Partial expressway closures also resulted in some deliveries taking longer than usual.

Heavy rain is forecast to continue in the Hokuriku region through August 28, with wholesalers remaining on alert for further disruption while prioritizing employee safety.

BUSINESS

By Ken Yoshino

Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…

By Philip Carrigan

Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…

By Kohei Hori

Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…

By Kohei Hori

Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…

By Takashi Ebisawa

Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…